Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | CHIEF SCIENTIFIC OFFICER | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 382,531 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Purchase · Acquired 6,035 · Balance 382,531 F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 6,035 | $4.15 | $25,045.25 |
DisclosureSEC source: 0001790340-26-000076 · wk-form4_1781640910.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,531 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 13:32 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 344,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000030 · wk-form4_1770298352.xml · derivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,000 Underlying: Class A Common Stock · 344,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:07 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,298 | $4.57 | $10,501.86 |
DisclosureSEC source: 0001790340-26-000012 · wk-form4_1768597660.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,496 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.57 to $4.571. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:30 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 14,880 | $1.43 | $21,248.64 |
DisclosureSEC source: 0001790340-25-000111 · wk-form4_1758141012.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,198 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 13:01 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 6,007 | $2.43 | $14,596.41 |
DisclosureSEC source: 0001790340-25-000087 · wk-form4_1750770096.xml · nonDerivative · entry 2 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,318 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.4101 to $2.4299. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 13:01 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 7,415 | $2.70 | $20,019.76 |
DisclosureSEC source: 0001790340-25-000087 · wk-form4_1750770096.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,311 Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:13 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 240,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000026 · wk-form4_1738962816.xml · derivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Class A Common Stock · 240,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 13:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 7,000 | $2.86 | $20,020.00 |
DisclosureSEC source: 0001790340-24-000034 · wk-form4_1711026361.xml · nonDerivative · entry 2 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,896 Read SEC document |
| March 15, 2024 Filed Mar 21, 2024 13:06 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 6,211 | $1.62 | $10,061.82 |
DisclosureSEC source: 0001790340-24-000034 · wk-form4_1711026361.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,896 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:12 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 130,900 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000008 · wk-form4_1707513136.xml · derivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,900 Underlying: Class A Common Stock · 130,900 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:16 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 187,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002758 · form4-02172023_040232.xml · derivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,000 Underlying: Class A Common Stock · 187,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:09 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,551 | $3.92 | $9,999.92 |
DisclosureSEC source: 0001415889-22-005796 · form4-05272022_010532.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,685 Read SEC document |
| March 23, 2022 Filed Mar 23, 2022 22:38 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,050 | $7.91 | $8,305.50 |
DisclosureSEC source: 0001415889-22-003305 · form4-03232022_030347.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,134 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:33 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 83,100 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001329 · form4-02142022_020226.xml · derivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,100 Underlying: Class A Common Stock · 83,100 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 22:30 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 322,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-006188 · form4-12222021_021254.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,084 F1 · price: Calculated using a value based on the average of the daily volume weighted average prices of the Class A common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the Closing Date, as that term is defined in the Share Purchase Agreement, dated as of December 22, 2021, by and among Immuneering Corporation, BioArkive, Inc. ("BioArkive"), and each of the shareholders of BioArkive, including Dr. Hall. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 3,404 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099733 · tm2123807-6_4seq1.xml · derivative · entry 4 Hall Brett Matthew · CIK 0001870437 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 1,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099733 · tm2123807-6_4seq1.xml · derivative · entry 3 Hall Brett Matthew · CIK 0001870437 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,353 | $15.00 | $20,295.00 |
DisclosureSEC source: 0001104659-21-099733 · tm2123807-6_4seq1.xml · nonDerivative · entry 2 Hall Brett Matthew · CIK 0001870437 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,393 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 5,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099733 · tm2123807-6_4seq1.xml · nonDerivative · entry 1 Hall Brett Matthew · CIK 0001870437 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.